
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-11-20 08:00:48Lincoln Pharmaceuticals Ltd has experienced a subtle yet significant shift in its technical momentum, moving from a bearish stance to a mildly bearish trend. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment for this micro-cap pharmaceutical stock.
Read MoreLincoln Pharmaceuticals Declines 2.48%: 6 Key Factors Shaping This Week’s Volatility
2026-11-01 10:00:35Key Events This Week 26 Oct: Downgrade to Sell amid technical weakness and modest growth 27 Oct: Technical momentum shifts to bearish amid mixed signals 28 Oct: Technical momentum shows mild improvement but remains cautious 29 Oct: Flat quarterly performance reported with margin contraction 30 Oct: Further technical downgrade and valuation shifts to attractive 30 Oct: Week closes at ₹501.95 (-2.48%) vs Sensex +2.12% <div class="stats...
Read More
Lincoln Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade
2026-10-30 08:00:50Lincoln Pharmaceuticals Ltd has experienced a significant shift in its technical momentum, prompting a downgrade from Hold to Sell by MarketsMojo on 28 Oct 2026. The micro-cap pharmaceutical company’s shares have declined sharply, reflecting deteriorating technical indicators and bearish signals across multiple timeframes.
Read More
Lincoln Pharmaceuticals Ltd Valuation Shifts to Attractive Amid Market Pressure
2026-10-30 08:00:48Lincoln Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This article analyses the company’s current price attractiveness in the context of its historical performance, peer comparisons, and broader market trends.
Read More
Lincoln Pharmaceuticals Ltd Reports Flat Quarterly Performance Amid Margin Pressure
2026-10-29 16:00:06Lincoln Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended September 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving its highest quarterly net sales to date, the company faced considerable margin contraction and profit pressures, prompting a downgrade in its Mojo Grade from Hold to Sell.
Read More
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-10-28 08:01:38Lincoln Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a strong day gain of 4.37%, the stock’s broader technical signals suggest caution as mixed readings from MACD, RSI, moving averages, and other momentum indicators paint a nuanced picture for investors.
Read More
Lincoln Pharmaceuticals Downgraded to Sell Amid Technical Weakness and Modest Growth
2026-10-26 08:06:02Lincoln Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by deteriorating technical indicators and subdued long-term financial growth. Despite some positive quarterly results and a net-debt-free balance sheet, the company’s overall outlook has weakened, prompting a reassessment of its quality, valuation, financial trend, and technical parameters.
Read More
Lincoln Pharmaceuticals Ltd Technical Momentum Shifts to Bearish Amid Mixed Signals
2026-10-26 08:00:36Lincoln Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating technical conditions, despite a modest price increase on 26 Oct 2026. Investors should carefully analyse the evolving chart patterns and momentum oscillators before making decisions.
Read MoreLincoln Pharmaceuticals Declines 5.82%: Death Cross and Technical Weakness Define Week
2026-10-25 11:00:34Key Events This Week Oct 19: Technical momentum shifts to mildly bearish amid mixed market signals Oct 23: Death Cross formation signals potential bearish trend Oct 23: Week closes at Rs.514.70 (-5.82%) Week OpenRs.546.50 Week CloseRs.514.70-5.82% <div class="stat-it...
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
30-Oct-2026 | Source : BSEPursuant to Regulation 47 of SEBI (LODR) Regulations 2015 we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the quarter and half year ended on September 30 2026.
Un-Audited Financial Results For The Quarter And Half Year Ended On September 30 2026.
29-Oct-2026 | Source : BSEUn-Audited Financial Results For the Quarter and Half year Ended on September 30 2026.
Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter And Half Year Ended On September 30 2026.
29-Oct-2026 | Source : BSEUn-Audited Financial Results For the Quarter and Half Year ended on September 30 2026.
Corporate Actions
No Upcoming Board Meetings
Lincoln Pharmaceuticals Ltd has declared 18% dividend, ex-date: 11 Sep 26
Lincoln Pharmaceuticals Ltd has announced 10:2 stock split, ex-date: 19 Mar 09
No Bonus history available
No Rights history available